CVE:RX - Get Free Report ) will be releasing its earnings data after the market closes on Thursday, May 16th. Analysts expect BioSyent to post earnings of C$0.08 per share for the quarter.
Get BioSyent alerts:
Sign Up
BioSyent (CVE:RX - Get Free Report ) last announced its quarterly earnings data on Wednesday, March 13th. The company reported C$0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of C$0.17 by C($0.05). The firm had revenue of C$8.27 million for the quarter, compared to analysts' expectations of C$8.80 million. BioSyent had a return on equity of 18.97% and a net margin of 20.45%.
BioSyent Stock Down 1.0 % Shares of CVE RX traded down C$0.09 during trading hours on Friday, hitting C$8.50. The stock had a trading volume of 2,200 shares, compared to its average volume of 5,705. The company has a market capitalization of C$98.69 million, a P/E ratio of 16.04 and a beta of 0.93. The firm's 50-day moving average price is C$8.60 and its two-hundred day moving average price is C$8.55. The company has a debt-to-equity ratio of 3.51, a quick ratio of 6.91 and a current ratio of 6.48. BioSyent has a 52 week low of C$7.03 and a 52 week high of C$9.26.
Insider Buying and Selling In other BioSyent news, insider BioSyent Inc. acquired 5,100 shares of the business's stock in a transaction that occurred on Monday, April 29th. The stock was acquired at an average price of C$8.55 per share, with a total value of C$43,627.95. Insiders own 38.45% of the company's stock.
About BioSyent (
Get Free Report )
BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.
Featured Articles
Before you consider BioSyent, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioSyent wasn't on the list.
While BioSyent currently has a "hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
